We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Abbott Diagnostics

Download Mobile App





PharmaJet and Abnova to Jointly Develop and Deliver COVID-19 mRNA Vaccine Using Needle-Free Injection Technology

By HospiMedica International staff writers
Posted on 20 May 2020
Print article
Image: The PharmaJet Stratis Needle-Free Injector (Photo courtesy of PharmaJet)
Image: The PharmaJet Stratis Needle-Free Injector (Photo courtesy of PharmaJet)
PharmaJet’s (Golden, CO, USA) Needle-free Injection System technology will be used to deliver a messenger RNA (mRNA) vaccine against SARS-CoV-2 that is being developed by Abnova Corporation (Taipei, Taiwan).

Abnova's DNAx Immune technology enables the rapid production of highly sensitive and specific antibodies for research, in vitro diagnostics, and therapeutic antibody applications. By leveraging the DNAx gene sequence antibody response bioinformatics, Abnova is accelerating the development of mRNA vaccines targeting infectious diseases and cancers. It has established a comprehensive portfolio of fully integrated solutions to address the needs for responding to SARS-CoV-2, including a novel adjuvant that can further increase the effectiveness of its mRNA candidate.

"We have taken a major next step toward mRNA vaccine development against COVID-19 based on the specific gene sequences generating successful antibody response from our DNAx Immune platform," said Dr. Wilber Huang, President and CEO, Abnova. "We would like to complement the mRNA immunization with a needle-free platform to further augment the protective antibody response against COVID-19 with an impactful clinical outcome."

"We are pleased to be collaborating with Abnova on the development of their SARS-CoV-2 mRNA vaccine," commented Chris Cappello, President and CEO, PharmaJet, "Our system has been found to improve the immune response of multiple RNA/DNA vaccines, in addition to its proven ease of administration in wide-scale immunization settings."

Related Links:
PharmaJet
Abnova



Print article

Channels

Copyright © 2000-2020 Globetech Media. All rights reserved.